

**Update: Seasonal Flu Vaccines for 2018-19**

NHS England has released its ‘definitive’ [**guidance**](https://lmcbuyinggroups.co.uk/admin/resources/nhse-name-2.pdf) for GP practices about which flu vaccines to use for the 2018-19 season.

NHS England is now advising all practices to use the adjuvanted trivalent vaccine (Fluad - Seqirus) for all patients over 65 and a quadrivalent vaccine for any ‘at risk’ groups including pregnant women aged 18-65 years.

This decision has been based on clinical evidence from the Joint Committee on Vaccination and Immunisation (JCVI) and cost effectiveness studies by Public Health England.

Suppliers of the adjuvanted trivalent and quadrivalent vaccines have given NHS England assurances that they will be able to cope with the increased demand for their vaccines.

Additional funding has been found to cover the additional costs of using the adjuvanted trivalent and quadrivalent vaccines, so practices do not need to worry about not being reimbursed.

Please note that practices will still need to order trivalent vaccines for any at risk patients age six months to two years as Fluenz, Fluad and quadrivalent vaccines aren’t licensed for this age group. MASTA, Mylan and Seqirus can provide vaccines suitable for children age six months and above. For more information on these discounts, please visit our website.

As this definitive guidance was released after most practices would have placed their vaccine order with their preferred supplier, we have spoken with the four companies we negotiated discounts with for the 2018-19 season to compile advice for those practices that now need to cancel or amend their original vaccine orders (see next pages).

If you have any questions, please call us on 0115 979 6910, email info@lmcbuyinggroups.co.uk or Live Chat with us via the website: <https://www.lmcbuyinggroups.co.uk/>.

To have full access to the website and the Buying Group discounts and service, please complete the registration form on the website: <https://www.lmcbuyinggroups.co.uk/members/>.

**Seqirus**

Seqirus is the only company producing an adjuvanted trivalent vaccine for over 65s for the 2018-19 season.

Our members still have access to their ‘early bird’ discount of 40.3% until 16 February 2018.

|  |  |
| --- | --- |
|  | **Orders before****16 February 2018 (40.3%)** |
| NHS Price | £9.79 |
| Dispensing fee\* | £2.209 |
| VAT (20%) | £1.96 |
| **Total NHS Reimbursement** | **£13.96** |
| Actual cost after discount+ | £5.84 |
| VAT (20%) | £1.17 |
| Total cost to practice | £7.01 |
| **Total Profit Per Dose (PPD)** | **£6.95** |

\* The dispensing fee illustrated is for guidance purposes only and is based on a non-dispensing practice dispensing up to 457 items a month under rules applying from 1 October 2017.

+ Discount based on order of less than 1000 doses. Additional discounts are available to those practices wanting to order more than 1000 doses.

**Contact Seqirus**

Tel: 01530 454288; Email: flu.salesuk@seqirus.com

**Pfizer**

Pfizer produce two trivalent vaccines for the UK market and we know many of our members have ordered with Pfizer and will now have to cancel their orders and move them to Seqirus for the adjuvanted trivalent and to MASTA or Mylan for quadrivalents for most of their patients.

Pfizer has confirmed that they will honour any changes and cancellations to the orders already placed with them by our members and that Pfizer customers will not be charged for cancelling their orders.

Please contact Pfizer as soon as possible to cancel any existing orders for their trivalent vaccines.

**Contact Pfizer**

Tel: 0800 089 4033; Email: vaccinesuk@pfizer.com

**MASTA**

MASTA have access to both trivalent and quadrivalent vaccines, so any existing customers can simply switch formulations for the 18-65s.

If you need to move part of your order from MASTA to Seqirus then please contact their flu team as soon as possible to discuss your requirements.

|  |  |
| --- | --- |
|  | **Quadrivalent (50%)** |
| NHS Price | £8.00 |
| Dispensing fee\* | £2.209 |
| VAT (20%) | £1.60 |
| **Total NHS Reimbursement** | **£11.81** |
| Actual cost after discount | £4.00 |
| VAT (20%) | £0.80 |
| Total cost to practice | £4.80 |
| **Total Profit Per Dose (PPD)** | **£7.01** |

\* The dispensing fee illustrated is for guidance purposes only and is based on a non-dispensing practice dispensing up to 457 items a month under rules applying from 1 October 2017.

**Contact MASTA**

Tel: 0113 238 7552; Email: fluteam@masta.org

**Mylan**

Mylan produce both trivalent and quadrivalent vaccines, so any existing customers can simply switch formulations for the 18-65s.

If you need to move part of your order from MASTA to Seqirus then please contact their flu team as soon as possible to discuss your requirements.

**Influvac QIV**

|  |  |
| --- | --- |
| NHS Price | £9.94 |
| Dispensing Fee\* | £2.209 |
| VAT (20%) | £1.99 |
| **Total NHS Reimbursement**  | **£14.14** |
| Actual cost after discount (50%) | £4.97 |
| VAT (20%) | £0.99 |
| Total cost to practice | £5.96 |
| **Total Profit Per Dose (PPD)**  | **£8.18** |

**Generic QIV**

|  |  |
| --- | --- |
| NHS Price | £8.00 |
| Dispensing Fee\* | £2.209 |
| VAT (20%) | £1.60 |
| **Total NHS Reimbursement**  | **£11.81** |
| Actual cost after discount (50%) | £4.00 |
| VAT (20%) | £0.80 |
| Total cost to practice | £4.80 |
| **Total Profit Per Dose (PPD)**  | **£7.01** |

\* The dispensing fee illustrated is for guidance purposes only and is based on a non-dispensing practice dispensing up to 457 items a month under rules applying from 1 October 2017.

**Contact Mylan**

Tel: 0800 358 7468; Email: flu@mylan.com